1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

  • February 2016
  • -
  • Delve Insight
  • -
  • 338 pages

Summary


DelveInsight’s, “Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all 99 pipeline drugs that fall under the category of Head and Neck Squamous Cell Carcinoma. Eli Lilly’s Exbitux (Cetuximab) is the first monoclonal antibody for head and neck cancer.
The report provides a detailed insight of all the pipeline drugs. Keytruda (Pembrolizumab) of Merck is one of the most promising drug candidates. Pipeline for Head and Neck cancer looks strong as many companies are coming up with the biosimilar versions of cetuximab like R-Pharm and Sorrento. Researchers are working to get next-generation treatments like antibody-drug conjugates or immunotherapy, which might yield better results than chemotherapy alone.

The report also provides a comparative analysis of therapeutics based on the molecule type, route of administration, etc. It also gives insights of other activities such as, agreements, joint ventures, partnerships, acquisitions and mergers.


Scope:

-The report, provides a Head and Neck Squamous Cell Carcinoma Landscape across the globe
-The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
-Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
-Coverage of the Head and Neck Squamous Cell Carcinoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
-The report reviews key players involved in the therapeutics development for Head and Neck Squamous Cell Carcinoma and also provide company profiling
-Pipeline products coverage based on various stages of development from NDA filings to discovery.
-Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Reasons to Buy

-Complete Pipeline intelligence and complete understanding over therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma
-Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
-Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
-Developing strategic initiatives to support your drug development activities.
-Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
-Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
-Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

Table of Contents:

- Head and Neck Squamous Cell Carcinoma Overview
- Epidemiology
- Diagnosis of Head and Neck Cancer
- Market Scenario
- Market Barriers
- Market Drivers
- Pipeline Therapeutics
- An Overview of Pipeline Products for Head and Neck Squamous Cell Carcinoma
- Therapeutics under Development by Companies
- Last Stage Products (Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Phase 0 stage Products
- Comparative Analysis
- Discovery and Pre-clinical stage Products
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Discontinued Products
- Dormant Products
- Companies Involved in Therapeutics Development
- Appendix
- DelveInsight Consulting Services
- About DelveInsight
- Contact Us
- Disclaimer

List of Tables:

- Table 1: Number of Products Under Development for Head and Neck Squamous Cell Carcinoma, 2016
- Table 2: Number of Products under Development by Companies, 2016
- Table 3: Last Stage Products (Phase III and Filed), 2016
- Table 4: Mid Stage Products (Phase II), 2016
- Table 5: Early Stage Products (Phase I and IND), 2016
- Table 6: Phase 0 stage Products , 2016
- Table 7: Discovery and Pre-clinical Stage Products , 2016
- Table 8: Assessment by Monotherapy Products,2016
- Table 9: Assessment by Route Of Administration, 2016
- Table 10: Assessment by Stage and Route Of Administration, 2016
- Table 11: Assessment by Molecule Type, 2016
- Table 12: Assessment by Stage and Molecule Type, 2016
- Table 13: Discontinued Products, 2016
- Table 14: Dormant Products, 2016
- Table 15: Companies Involved in Therapeutic Development, 2016

List of figures:


- Figure 1: Percent of New Cases by Age Group: Head and Neck Cancer, 2016
- Figure 2: Percent of Deaths by Age Group: Head and Neck Cancer, 2016
- Figure 3: Number of Products under Development Head and Neck Squamous Cell Carcinoma, 2016
- Figure 4: Last Stage Products (Phase III) 2016
- Figure 5: Mid Stage Products (Phase II), 2016
- Figure 6: Early Stage Products (Phase I and IND), 2016
- Figure 7: Phase 0 stage Products, 2016
- Figure 8: Discovery and Pre-clinical Stage Products, 2016
- Figure 9: Assessment by Monotherapy Products, 2016
- Figure 10: Assessment by Combination Products, 2016
- Figure 11: Assessment by Route of Administration, 2016
- Figure 12: Assessment by Stage and Route of Administration, 2016
- Figure 13: Assessment by Molecule Type, 2016
- Figure 14: Assessment by Stage and Molecule Type, 2016


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Catheters, Needles, and Cannulas Market Outlook: 2016-2021

Global Catheters, Needles, and Cannulas Market Outlook: 2016-2021

  • $ 6575
  • Industry report
  • December 2016
  • by Meticulous Research

With the continuous development in the medical field due to growing need to curtail increasing healthcare costs, rising focus on patient safety, mounting aging population, and rising prevalence of various ...

Asia-Pacific Ophthalmic Lasers Market Outlook to 2022

Asia-Pacific Ophthalmic Lasers Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

Asia-Pacific Ophthalmic Lasers Market Outlook to 2022 Summary GlobalData’s new report, "Asia-Pacific Ophthalmic Lasers Market Outlook to 2022", provides key market data on the Asia-Pacific Ophthalmic ...

North America Vitreo Retinal Surgery Devices Market Outlook to 2022

North America Vitreo Retinal Surgery Devices Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

North America Vitreo Retinal Surgery Devices Market Outlook to 2022 Summary GlobalData’s new report, "North America Vitreo Retinal Surgery Devices Market Outlook to 2022", provides key market data on ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.